Evidence map›Paper›PMID 27727493›Full record

ArticleProtein science : a publication of the Protein Society2017

Germinal-center kinase-like kinase co-crystal structure reveals a swapped activation loop and C-terminal extension.

Douglas Marcotte, Mia Rushe, Robert M Arduini, Christine Lukacs, Kateri Atkins, Xin Sun, Kevin Little, Michael Cullivan, Murugan Paramasivam, Thomas A Patterson and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. MAP4K3/GLK in autoimmune disease, cancer and aging.Journal of biomedical science · 2019
    Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Douglas MarcotteDepartment of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142.
Mia RusheDepartment of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142.
Robert M ArduiniDepartment of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142.
Christine LukacsBeryllium Discovery Corp., 3 Preston Court, Bedford, MA, 01730.
Kateri AtkinsBeryllium Discovery Corp., 3 Preston Court, Bedford, MA, 01730.
Xin SunDepartment of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142.
Kevin LittleDepartment of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142.
Michael CullivanDepartment of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142.
Murugan ParamasivamDepartment of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142.
Thomas A PattersonDepartment of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142.
Thomas HessonDepartment of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142.
Timothy D McKeeDepartment of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142.
Tricia L May-DrackaDepartment of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142.
Zhili XinDepartment of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142.
Andrea Bertolotti-CiarletDepartment of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142.
Govinda R BhisettiDepartment of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142.
Joseph P LyssikatosDepartment of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142.
Laura F SilvianDepartment of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142.
Biogen (United States) · USBeryllium (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Germinal-center kinase-like kinase (GLK, Map4k3), a GCK-I family kinase, plays multiple roles in regulating apoptosis, amino acid sensing, and immune signaling. We describe here the crystal structure of an activation loop mutant of GLK kinase domain bound to an inhibitor. The structure reveals a weakly associated, activation-loop swapped dimer with more than 20 amino acids of ordered density at the carboxy-terminus. This C-terminal PEST region binds intermolecularly to the hydrophobic groove of the N-terminal domain of a neighboring molecule. Although the GLK activation loop mutant crystallized demonstrates reduced kinase activity, its structure demonstrates all the hallmarks of an "active" kinase, including the salt bridge between the C-helix glutamate and the catalytic lysine. Our compound displacement data suggests that the effect of the Ser170Ala mutation in reducing kinase activity is likely due to its effect in reducing substrate peptide binding affinity rather than reducing ATP binding or ATP turnover. This report details the first structure of GLK; comparison of its activation loop sequence and P-loop structure to that of Map4k4 suggests ideas for designing inhibitors that can distinguish between these family members to achieve selective pharmacological inhibitors.

Indexed as

Mutation, MissenseAmino Acid SubstitutionCrystallography, X-RayHumansProtein DomainsProtein Kinase InhibitorsProtein Serine-Threonine KinasesProtein Structure, SecondaryMAP4K3 protein, humanProtein Kinase InhibitorsProtein Serine-Threonine Kinasesactivation loopaminopyrrolopyrimidine inhibitorcrystal structureGCK-Igerminal-center kinase-like kinaseGLKMap4k3PEST sequence

Identifiers

PMID27727493
PMCPMC5275742
OpenAlexW2539333586

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.